PARKINSON'S DISEASE NEWS

25th May 2011 - News release

PROSAVIN CLINICAL TRIAL DATA FOR PARKINSON'S DISEASE

Oxford BioMedica, a leading gene therapy company, have announced clinical data from a Phase I/II clinical trial of ProSavin for the treatment of Parkinson’s Disease. They claim : an average improvement in motor function of 43%, a maximum improvement of 61%, an increase in "on" time of 3 hours, and an decrease in "off" time of 4 hours. Two doses have been tested. For more information go to the News release. ProSavin uses Oxford BioMedica's own LentiVector gene delivery technology to deliver the genes for three enzymes that are required for the formation of dopamine. The product is administered locally to the relevant region of the brain in order to increase the brain's own capacity for the formation of dopamine. For more information go to ProSavin.

However, only nine patients have so far been tested, and only for part of the intended duration of the clinical trial. The claim of increased "on" time and decreased "off" time has come only from two patients, and had been entirely self reported by the patients themselves. The claim of an average improvement in motor function of 43%, and a maximum improvement of 61% comes from only three of the patients who have been tested for the least time. It was not the actual average improvement of the patients, which was much less. Those patients tested for the longest actually declined in their improvement as time wore on. For more current news go to Parkinson's Disease News.

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports